Pemvidutide (Altimmune, formerly ALT-801) is an investigational once-weekly injectable that agonizes two receptors: GLP-1 and glucagon. If semaglutide works on a single incretin pathway and retatrutide on three, pemvidutide sits deliberately in the middle — and its whole design pitch is not raw weight-loss magnitude but the kind of tissue it takes off. It is not approved anywhere. Here is what the Phase 2 data actually show, and where the marketing gets ahead of the evidence.
What it is, and the lean-mass idea
The GLP-1 arm drives the appetite suppression familiar from every drug in this class. The novel piece is glucagon-receptor agonism: glucagon acts directly on the liver to stimulate fatty-acid oxidation and raise energy expenditure. The theory Altimmune builds on that is a specific one. A recognized downside of aggressive GLP-1 weight loss is that a meaningful share of the lost weight is lean mass, not just fat — the muscle-loss concern we cover in detail in GLP-1s and lean-mass loss. Pemvidutide's design goal is that the glucagon-driven fat mobilization biases the loss toward adipose tissue and spares more lean mass. That is the hypothesis. Whether it translates into a real, comparative advantage is a separate question the trials have not yet settled.
MOMENTUM: the Phase 2 obesity trial
MOMENTUM was a 48-week, randomized, double-blind, placebo-controlled Phase 2 trial in 391 adults with obesity or overweight (with at least one comorbidity, and without diabetes), randomized across 1.2 mg, 1.8 mg and 2.4 mg doses or placebo.[1] At 48 weeks, mean weight loss was about 10.3%, 11.2% and 15.6% at the three ascending doses, versus roughly 2.2% on placebo.[1] The trial is registered on ClinicalTrials.gov as NCT05295875.[2]
The number the company emphasized was not the headline percentage but the body composition. Altimmune reported that only about 25.5% of the weight lost came from lean mass, with roughly 74.5% from fat mass.[1] Read honestly, that is an encouraging within-trial finding, but it is not evidence of superiority: it was measured against this trial's own placebo arm, not head-to-head against semaglutide or tirzepatide. Cross-trial fat/lean ratios are notoriously sensitive to measurement method and population, so the lean-preservation story should be treated as a promising design hypothesis, not a settled ranking.
On magnitude alone, the −15.6% at 2.4 mg is in the neighborhood of semaglutide (about −15% in STEP 1) and below tirzepatide (about −21% in SURMOUNT-1); the dual-versus-dual mechanics are worth reading alongside our tirzepatide versus semaglutide comparison. Pemvidutide's argument was never that it loses the most weight — it is that it may lose a better composition of weight.
IMPACT: the Phase 2b MASH trial
The second pillar is the liver. Pemvidutide's glucagon component acts on hepatocytes directly, which is why the program has always targeted metabolic dysfunction-associated steatohepatitis (MASH). An earlier 12-week Phase 1b study in MASLD already showed large relative reductions in liver fat content — about 68.5% at the 1.8 mg dose versus 4.4% on placebo, with roughly 56% of patients on that dose normalizing liver fat.[3]
IMPACT is the larger, biopsy-confirmed test: an ongoing 48-week, randomized, double-blind Phase 2b trial in 212 patients with F2 or F3 fibrosis MASH, dosed at 1.2 or 1.8 mg without titration. At the 24-week readout, pemvidutide met the primary endpoint of MASH resolution without worsening of fibrosis: about 58% (1.2 mg) and 52% (1.8 mg) versus 20% on placebo.[4]But it did not meet the co-primary endpoint of fibrosis improvement without worsening of MASH at 24 weeks — roughly 33% and 36% versus 28% on placebo, a difference that was not statistically significant.[4] The drug was well tolerated, with few discontinuations. Fibrosis is slow to move, and the 24-week miss on fibrosis was the caveat to keep front of mind at that readout.
The longer-duration data have since arrived. At the 48-week IMPACT readout, presented at the EASL Congress in 2026, a composite fibrosis-biomarker endpoint — a ≥0.5-point reduction in Enhanced Liver Fibrosis (ELF) score combined with a ≥30% reduction in liver-stiffness measurement — was reached by roughly 27.8% of patients on 1.2 mg and 32.4% on 1.8 mg, versus 3.2% on placebo.[5] Weight loss on 1.8 mg also continued through 48 weeks without plateauing, reaching about 7.5%.[5] A biomarker composite is not the same thing as the biopsy-read fibrosis-improvement endpoint IMPACT missed at 24 weeks, so this is supportive evidence rather than a reversal of that earlier result — but it is a meaningfully stronger signal than the 24-week data alone conveyed. In January 2026 the FDA granted pemvidutide Breakthrough Therapy Designation for MASH, and following an end-of-phase-2 meeting, Altimmune has aligned with the FDA on a registrational Phase 3 trial — PERFORMA — planned to begin in the second half of 2026, with a 52-week readout not expected before 2029.[6]
The honest caveats
Three things deserve emphasis. First, the MOMENTUM obesity program and the 24-week IMPACT MASH data are Phase 2 — a Phase 3 MASH trial (PERFORMA) is now planned but has not yet enrolled, so there is still no completed Phase 3 efficacy or outcomes program and no long-term safety database. Second, the glucagon component is the double-edged part of the mechanism: it is what drives the liver-fat and possible lean-sparing effects, but glucagon agonism is also what demands careful, long-horizon monitoring of glycemia, heart rate and cardiovascular safety. Third, the lean-mass claim is a hypothesis under test, not a proven edge; it needs head-to-head, DXA-standardized comparison before anyone should call it superior on body composition. And to be explicit: pemvidutide is not approved and is not legitimately available outside a clinical trial.
The honest bottom line
Pemvidutide is one of the more interesting bets in the field precisely because it is not chasing the biggest number — it is chasing better fat-to-lean composition and direct liver benefit from a two-receptor design. The MOMENTUM composition data, the IMPACT MASH-resolution result, and the 48-week fibrosis-biomarker composite are genuine, encouraging Phase 2b signals, and they carried enough weight to earn Breakthrough Therapy Designation and a planned Phase 3 trial. But a met endpoint and a missed co-primary endpoint in the same MASH trial is still the core of the story: real promise, unfinished proof. Until PERFORMA reports, the appropriate posture is interested caution, not a verdict.